Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the
growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Chemoembolization kills tumor cells by carrying chemotherapy drugs
directly into the tumor and blocking the blood flow to the tumor. Giving bevacizumab together
with chemoembolization may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving bevacizumab together with
chemoembolization works in treating patients with liver cancer that cannot be removed by
surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Yale University
Collaborators:
National Cancer Institute (NCI) Northwestern University